Revenue (Quarterly)

Revenue: The sum of all revenue fields included for a company's operating activities.

BioMarin Pharmaceutical Inc. (BMRN) had Revenue of $989.71M for the most recently reported fiscal quarter, ending 2026-06-30.

Quarterly Annual

Figures for fiscal quarter ending 2026-06-30

Income Statement Financials
Revenue	$989.71M
Net Income	$44.76M
Cost of Goods Sold	$202.79M
Gross Profit	$786.91M
Operating Expenses	$878.79M
Operating Income	$110.92M
Non-Operating Income/Expense	$-49.54M
Pre-Tax Income	$61.38M
Normalized Pre-Tax Income	$61.38M
Income after Taxes	$44.76M
Income from Continuous Operations	$44.76M
Consolidated Net Income/Loss	$44.76M
Normalized Income after Taxes	$44.76M
EBIT	$110.92M
EBITDA	$209.01M
Weighted-Average Shares Outstanding (Basic)	193.42M
Weighted-Average Shares Outstanding (Diluted)	194.47M
Earnings per Share (EPS) (Basic)	$0.23
Earnings per Share (EPS) (Diluted)	$0.23
Balance Sheet Financials
Current Assets	$3.97B
Property, Plant, and Equipment	$989.99M
Long-Term Assets	$7.75B
Total Assets	$11.72B
Current Liabilities	$1.66B
Long-Term Debt	$3.53B
Long-Term Liabilities	$3.74B
Total Liabilities	$5.40B
Common Equity	$6.32B
Tangible Shareholders Equity	$786.58M
Shareholders Equity	$6.32B
Common Shares Outstanding	193.54M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$388.76M
Cash Flow from Investing Activities	$-4.38B
Cash Flow from Financial Activities	$3.55B
Beginning Cash	$1.31B
End Cash	$874.00M
Increase/Decrease in Cash	$-437.67M
Stock-Based Compensation	$119.15M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	2.39
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.36
Debt to Equity Ratio	0.66
Gross Margin	79.51%
Operating Margin	11.21%
EBIT Margin	11.21%
EBITDA Margin	--
Pre-Tax Profit Margin	6.20%
Profit Margin	4.52%
Free Cash Flow	$339.02M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.08
Inventory Turnover	0.11
Receiveable Turnover	0.93
Days Sales in Receivables	96.49
Return on Equity	0.71%
Return on Tangible Equity	5.69%
Return on Assets	0.38%
Return on Investments	0.45%
Book Value Per Share	$32.66
Free Cash Flow per Share	$1.74
Operating Cash Flow per Share	$2.00

Data from Zacks Investment Research, Inc.